Business / Finance

RSS

Ascendancy Healthcare signs multi-year collaboration with Quintiles

Ascendancy Healthcare, Inc. dedicated to the commercialization of therapeutic products to meet unmet medical needs in China and other high-growth Asian markets, announced today a multi-year collaboration with Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services.

25 Jul 2013

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Mylan Inc. today confirmed that Mylan Pharmaceuticals Inc. and Orion Corporation have entered into a settlement and license agreement settling the parties litigation in connection with Mylan's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Carbidopa/Levodopa/Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg.

25 Jul 2013

NeuroMetrix announces business and financial highlights for second quarter

NeuroMetrix, Inc. (the "Company"), a medical device company focused on the treatment of the neurological complications of diabetes, today reported business and financial highlights for the second quarter ended June 30, 2013.

25 Jul 2013

Magellan Health Services announces financial results for second quarter 2013

Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.

25 Jul 2013

Colgate reports worldwide Net sales of $4,346 million in second quarter 2013

Colgate-Palmolive Company today reported worldwide Net sales of $4,346 million in second quarter 2013, an increase of 2.0% versus second quarter 2012. Global unit volume grew 4.0%, pricing increased 1.0% and foreign exchange was negative 3.0%. Organic sales (Net sales excluding foreign exchange, acquisitions and divestments) grew 5.5%.

25 Jul 2013

NxStage Medical revenue increases 11% to $65.5 million in Q2 2013

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported second quarter financial results with total revenue at the top end of its guidance range.

25 Jul 2013

Teva, Lonza decide to discontinue biosimilars collaboration

Teva Pharmaceutical Industries and Lonza Group today announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars.

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

Mastech Holdings revenues increase 14% to $28.9 million in Q2 2013

Mastech Holdings, Inc., a national provider of Information Technology and Specialized Healthcare staffing services, announced today its financial results for the second quarter ended June 30, 2013.

24 Jul 2013

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.

24 Jul 2013

FMC acquires all shares of Epax for $345 million

FMC Corporation today announced that it has acquired all of the shares of Epax Nutra Holding III AS (Norway) and Epax UK Holding III AS (United Kingdom) (together, "Epax"), a leading manufacturer of high purity, premium grade Omega-3 fatty acid concentrates that are used in nutraceuticals, pharmaceuticals and food.

24 Jul 2013

Baylor Research Institute, Novartis sign license agreement for canakinumab

Baylor Research Institute, the research arm of Baylor Health Care System, announced that it has signed an agreement with Novartis to non-exclusively license Baylor's patents pertaining to the treatment of Systemic Onset Juvenile Idiopathic Arthritis using interleukin-1 beta antagonists.

24 Jul 2013

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Hopes are high for a new and improved tuberculosis vaccine: Serum Institute of India is planning on taking a promising vaccine - originally developed in Germany - and introducing it into the clinical setting.

23 Jul 2013

AMRI receives a Form 483 from the FDA for Burlington pharmaceutical manufacturing facility

As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.

23 Jul 2013

DaVita acquires dialysis operations of Malaysia's CDC Group

DaVita®, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, today announced the acquisition of the dialysis operations of Malaysia's Caring Dialysis Centre Group by DVA (Malaysia) Sdn Bhd.

22 Jul 2013

Moberg Pharma granted exclusive rights to market Kerasal Nail in China

Moberg Pharma AB today announced that Menarini Asia-Pacific, a member of the Menarini Group - a top 40 global pharmaceutical company - has been granted the exclusive rights to market and sell Kerasal Nail in China. The companies now intend to seek marketing authorization for the product in the Chinese market.

22 Jul 2013

Toshiba, Unfors RaySafe partner to improve clinical staff safety during interventional procedures

To improve clinical staff safety during interventional procedures and help monitor radiation dose, Toshiba America Medical Systems, Inc. has partnered with Unfors RaySafe, Inc. to offer a new dose monitoring and management tool for Infinix-i cardiovascular X-ray systems. The Unfors RaySafe i2 displays real-time dose exposure information, helping to make exams safer for all clinical staff.

22 Jul 2013

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.

22 Jul 2013

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

An investigation undertaken by Novozymes Biopharma DK has shown that when the corticosteroid dexamethasone is formulated in a cross-linked Hyaluronic acid (HA) hydrogel, the drug’s in vitro release time increases from under 10 minutes to approximately 15 hours. In addition, the in vivo half-life of dexamethasone is shown to plateau with stable dexamethasone concentration up to four hours after injection.

22 Jul 2013